<?xml version="1.0" encoding="UTF-8"?>
<p id="p0015">Among several potential drugs tested for efficacy in treatment of SARS-CoV-2 infection,
 <xref rid="bib16" ref-type="bibr">
  <sup>16</sup>
 </xref> remdesivir (GS-5734; Gilead Sciences Inc., Foster City, CA, USA) is shown to be the most promising and hopeful anti-viral therapeutic. It works by targeting viral RNA-dependent RNA polymerase (RdRp) while evading proofreading by viral exoribonuclease,
 <xref rid="bib17" ref-type="bibr">
  <sup>17</sup>
 </xref> resulting in premature termination of viral RNA transcription. Unlike other nucleotide analogues, remdesivir is a phosphoramidate prodrug with broad-spectrum activity against many virus families, including 
 <italic>Filoviridae</italic>, 
 <italic>Paramyxoviridae</italic>, 
 <italic>Pneumoviridae</italic>, and 
 <italic>Orthocoronavirinae</italic> (such as pathogenic SARS-CoV and Middle East respiratory syndrome coronavirus [MERS-CoV]).
 <xref rid="bib18" ref-type="bibr">
  <sup>18</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib19" ref-type="bibr">
  <sup>19</sup>
 </xref>
</p>
